A venture capital firm founded in 2018 and is based in the US invests in companies dedicated to working on the intersection of biology, technology, and data science. The firm is focused on early-stage investments from Seed to Series A and also dedicates funds to follow-on investment. Initial check sizes are usually between $1-2M but can fall outside of this range on a case-by-case basis. The firm will consider global opportunities.

The firm invests in the intersection of biology, technology, and data science and the areas of interest fall beyond traditional sectors. The firm is focused on (1) technology driving biology (miniaturization, automation, data sciences); (2) biology as technology (synthetic biology, genetic engineering, stem cells); (3) biology beyond healthcare (agriculture, chemicals/industrials, consumer). The firm will consider cutting edge therapeutics/drug development and platform technologies and diagnostics, is not interested in traditional medical devices or digital health.

The firm focuses on privately owned, early stage companies and is open to working with all types of management teams. The firm likes to step in early and prefers to act as the lead investor, but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a non-profit organization with offices in the US closed an initial fund of $50M USD dedicated to early-stage life science ventures from Series A to C. The initial size of investment ranges from $250k-2M and the firm aims to invest in 10 companies in the upcoming year. The firm prefers to invest in US-based companies but is open to global opportunities.

The firm is niched on four key areas of focus: benign hematology, transfusion medicine, cell therapy, and infectious diseases. The firm will consider therapeutics, diagnostics, and medical devices. The firm will consider therapeutics of all modalities from Pre-Clinical to Phase II. Within diagnostics, the firm is opportunistic and looks at technologies in clinical phases or on the market (must include proof of concept). Within medical devices, the firm is open to all technologies, but is more interested in cell therapy-enabling technologies in clinical phases or on the market (must include proof of concept). Focused on the need for blood-related and cellular technologies, the firm is interested in making not only a financial, but humanitarian investments that also tie back to the parent company.

The firm highly values working with a management team that is 100% committed to the project. The firm prefers that the team has an even distribution of members with scientific and commercial expertise. The firm is a strategic co-investor and seeks to work with the respective knowledge experts on the team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a global company has offices in US and Europe. This fund makes equity investments in early stage companies several industries, including healthcare and life sciences. The firm typically leads or co-leads rounds as a member of a syndicate of investors, and is actively seeking new investment opportunities across all funds.

Within life sciences, the firm is looking for early stage companies working primarily within therapeutics, but is open to other sectors and has made investments in medical devices, diagnostics, and digital health. The firm seeks to invest in areas of strategic interest to its parent company including Immunology (Autoimmune), Oncology, Immuno-oncology, and Fertility. The firm generally looks for companies with novel first-in-class preclinical stage assets as well as novel platform technologies. In addition, the firm is seeking innovation for process, research and/or applied solutions.

The firm is looking for privately held companies with experienced management teams able to take innovative solutions into commercially viable products. The firm looks to take an active role following investing taking a board seat. The firm is able to invest globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in the US represents approximately 2100 doctors, HNW investors, and angel investors. The firm invests in, but is not limited to, biotechnology, medical devices, and pharmaceuticals. Typical allocation size is $100k-250k per investor, participating in both leading investments and co-investing. The firm invests in companies worldwide, with no specific geographic preferences. Recently, the firm had 3 exits in the life science sector.

The firm is opportunistic in terms of sectors of interest. The firm invests in biotechnology, medical devices, pharmaceuticals, and anything relevant to life sciences that seems to be a good opportunity for the firm. The firm is open to all financial rounds and all stages of development as well as orphan diseases and all indications.

The firm does not have any management team requirements, although depending on the case, taking a board seat may be requested.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large high-tech biological company focuses on rapid diagnostics in China – the company has gone public a few years ago. Apart from their headquarters, the firm has an international presence in Europe, Asia, and North America. The firm is open to different forms of partnership including license-in, joint venture, buyout, and equity investment for early-stage companies.

The firm has a strong interest in IVD sectors for innovative products addressing the unmet needs of healthcare providers.

The firm is open to global opportunities while preferring companies with a Chinese angle.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An evergreen fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The firm is most interested in companies addressing North Asia, USA, Europe, and LATAM markets.

The firm will invest in therapeutics, medical devices, diagnostics, and digital health products. In therapeutics, the firm is currently most interested in cell and gene therapy, nucleic acid drugs, and all novel drug delivery products. The firm prefers to invest from early clinical stage (Phase I) and beyond. In medical devices, the firm is opportunistic and is open to all types of technologies. In diagnostics, the firm is primarily interested in IVD and diagnostics tools. The firm prefers to invest in products that have entered clinical testing, and is open to investing in both 510k and PMA devices. Lastly, in digital health, the firm is open to all types of technologies including those that leverage AI. In terms of indications, the firm is most interested in chronic disease therapy / care, neuron disorders, and oncology.

The firm is looking for competent, experienced, and reliable management teams when considering investment. The fund typically requires a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investor and venture builder based in the US invests in pre-clinical therapeutics companies, frequently taking a majority stake and playing an active role in the company’s development. The firm is open to all therapeutic types and indications, currently they have a particular interest in Infectious Disease technologies to partner and or invest with a current portfolio company. The firm will generally invest $1-5M, and will invest globally, with previous investments in North America, Europe and Israel.

The firm is interested only in therapeutics companies, but will consider all types of therapeutics in all indications. The firm invests from discovery to preclinical stage and will support companies development efforts.

The firm prefers to lead and take a majority stake in their portfolio companies, and then act as a venture builder. The firm is interested only in companies that have strong IP portfolios.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.